IDEAYA Biosciences Inc. (IDYA) has announced positive clinical data from the 30 mg expansion dose of its phase II trial of IDE397 monotherapy in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients.
Among the 18 evaluable patients in the trial, the Overall Response Rate was 39% and the Disease Control Rate was about 94%. Furthermore, tumor shrinkage was observed in approximately 78% of patients (14 out of 18), and the ctDNA molecular response rate was an impressive 81%, according to the company.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com